First, liraglutide, and then voglibose were added to insulin treatment, but continuous glucose monitoring (CGM) using iPro2® (Medtronic Japan, Tokyo, Japan) revealed that treatment with insulin lispro 3 U before each meal, liraglutide 0.9 mg before breakfast and voglibose 0.2 mg before lunch was not able to suppress either marked diurnal hyperglycemia or the early-morning hypoglycemia (Fig. 2a). Here, INS is linked to Hyperglycemia.